Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Holding RVMD?
Track your performance easily
RVMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.93 - $62.40
Previous CloseN/A
Volume180.68K
Average Volume (3M)1.77M
Market Cap
$7.28B
Enterprise Value$6.10B
Total Cash (Recent Filing)$9.08M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Mar 03, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.59
Shares Outstanding182,349,820
10 Day Avg. Volume1,400,116
30 Day Avg. Volume1,770,148
Standard Deviation0.17
R-Squared0.20
Alpha-0.00009
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9059.36
Price to Cash Flow (P/CF)-12.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue8.23K
Enterprise Value/Gross Profit527.08
Enterprise Value/Ebitda-11.38
Forecast
1Y Price Target
$74.00Price Target Upside85.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Revolution Medicines News
Bulls Say, Bears Say
Bulls Say
Clinical DataEncouraging clinical data from the innovative RAS(ON) platform, coupled with the large addressable population of RAS-dependent cancers, support a positive long-term outlook for RVMD.
Clinical TrialsThe initiation of the randomized Phase 3 RASolve 301 trial will evaluate RMC-6236 against standard treatments in NSCLC, showing confidence in its efficacy.
Strategic ExpansionExpansion into earlier lines of treatment is seen as a potential upside opportunity, allowing RevMed to capture a significant portion of new patients in NSCLC, CRC, and PDAC.
Bears Say
Efficacy And Tolerability ConcernsShare weakness may have been driven by new concerns on ‘6236 tolerability following dose reduction in NSCLC.
Safety Profile IssuesThe safety profile worsened on the margin from the prior update with higher rates of adverse events.
Trial DelaysThere is a slight delay in the initiation of Phase 3 trials for RMC-6236 in second-line RAS-mutant NSCLC, now expected to start in the first quarter of 2025.
---
Ownership Overview
6.45% Insiders
25.68% Mutual Funds
0.05% Other Institutional Investors
52.85% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $25.93 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $7.28B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Nov 06, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.893 by -$0.047.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -0.99.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 182,349,820 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.893. Following the earnings report the stock price went down -0.539%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
---
Revolution Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.00 (85.46% Upside)
$74.00 (85.46% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $60.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.72%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
79.12%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
RVMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong progress in clinical trials for RMC-6236 and RMC-9805, a robust financial position, and future plans for pipeline expansion. However, increased expenses and a delay in the lung cancer trial posed challenges.Read More>---
RVMD Stock 12 Month Forecast
Average Price Target
$74.00
▲(85.46% Upside)
Technical Analysis
Immatics
―
Blueprint Medicines
―
Kodiak Sciences
―
Foghorn Therapeutics
―
RAPT Therapeutics
―
MacroGenics
―
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+25.85%
reiterated a buy rating 2 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +25.85% per trade.
---